Transcranial Direct Current Stimulation for Stroke Recovery
Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that delivers weak electrical currents (typically 1–2 mA) through scalp electrodes to modulate cortical excitability. Over the past two decades, tDCS has generated considerable interest as a potential adjunct to stroke rehabilitation due to its simplicity, low cost, and excellent safety profile. However, despite promising early proof-of-concept studies, large multicenter randomized controlled trials have consistently failed to demonstrate meaningful benefit for motor recovery. The 2020 Cochrane review concluded that evidence does not support routine clinical use of tDCS for motor rehabilitation after stroke.
🔹 Bottom Line: tDCS for Stroke Recovery
- Large RCTs negative: Both the NETS trial (2024, 119 patients) and TRANSPORT2 trial (2025, 129 patients) found NO benefit for motor recovery despite theoretical promise.
- Cochrane 2020: Analysis of 67 studies (1,729 patients) concluded evidence does NOT support clinical use of tDCS for motor rehabilitation.
- Aphasia: More encouraging — meta-analyses show modest but consistent naming improvements (SMD ~0.25) when combined with speech therapy.
- Safety: Excellent profile — no seizures in major trials; side effects limited to mild tingling, itching, or skin redness.
- Advantages: Inexpensive (~$1,000 device), portable, simple to administer, can be used concurrently with therapy.
- FDA status: Not approved for stroke rehabilitation; remains investigational.
Mechanism of Action
Unlike TMS, which directly induces action potentials, tDCS delivers subthreshold currents that modulate neuronal membrane potential without directly triggering neuronal firing. The effects depend on electrode polarity:
- Anodal stimulation: Depolarizes neuronal membranes → increases cortical excitability
- Cathodal stimulation: Hyperpolarizes neuronal membranes → decreases cortical excitability
The therapeutic rationale mirrors that of TMS — rebalancing interhemispheric inhibition after stroke. Anodal tDCS to the ipsilesional motor cortex aims to enhance excitability of the damaged hemisphere, while cathodal tDCS to the contralesional hemisphere aims to reduce excessive inhibition from the unaffected side. Dual or bi-hemispheric tDCS applies both approaches simultaneously.
At the cellular level, tDCS is thought to induce long-term potentiation (LTP) and long-term depression (LTD)-like plasticity through NMDA receptor-dependent mechanisms, potentially enhancing the effects of concurrent rehabilitation training.
Types of tDCS Protocols
| Protocol | Electrode Placement | Effect | Typical Parameters |
|---|---|---|---|
| Anodal tDCS | Anode over ipsilesional M1; cathode over contralateral orbit | Excitatory to affected hemisphere | 1–2 mA, 20 min |
| Cathodal tDCS | Cathode over contralesional M1; anode over contralateral orbit | Inhibitory to unaffected hemisphere | 1–2 mA, 20 min |
| Dual/Bi-hemispheric | Anode ipsilesional M1; cathode contralesional M1 | Combined excitation + inhibition | 1–2 mA, 20 min |
| HD-tDCS | Multiple small electrodes in focal array (4×1 ring) | More precise targeting | 1–4 mA, 20 min |
Applications in Stroke Recovery
Upper Limb Motor Recovery
Early small proof-of-concept studies suggested tDCS could enhance motor learning and rehabilitation outcomes. However, large, well-controlled multicenter trials have consistently failed to replicate these findings.
Key negative trials:
- NETS Trial (2024): Multicenter, double-blind RCT of 119 patients with subacute ischemic stroke. Anodal tDCS (1 mA, 20 min) applied to ipsilesional M1 over 10 sessions combined with standardized rehabilitation. Result: No difference — both groups improved by ~9 FMA-UE points (p=0.820). Safe, but no efficacy signal.
- TRANSPORT2 (2025): Phase 2 RCT of 129 patients, 1–6 months post-stroke. Compared sham vs 2 mA vs 4 mA bi-hemispheric tDCS combined with modified constraint-induced movement therapy (mCIMT). Result: No benefit at either dose over mCIMT alone.
- Cochrane Review (2020): 67 studies, 1,729 patients. Found low-to-moderate quality evidence suggesting possible benefit for activities of daily living, but no effect on arm function. Concluded: "Evidence does not support the use in clinical practice of tDCS to improve ADL."
🔴 Important: Large RCTs Have Been Negative
- Despite theoretical promise, NETS and TRANSPORT2 found no benefit for motor recovery
- Cochrane 2020 does not support routine clinical use of tDCS for motor rehabilitation
- Contrast with TMS, which has Level A evidence for motor recovery
- tDCS for motor recovery remains investigational
Post-Stroke Aphasia
In contrast to motor recovery, tDCS for post-stroke aphasia has shown more consistent, albeit modest, benefits. Multiple meta-analyses support its use as an adjunct to speech-language therapy (SLT), particularly for naming deficits.
Key evidence:
- Network meta-analysis (2020, 25 RCTs): Anodal tDCS improved functional communication compared to sham. Cathodal and dual tDCS also showed benefits for specific language domains.
- Meta-analysis (2025, 12 RCTs, 400 patients): tDCS significantly improved naming in post-stroke aphasia (SMD 0.25, 95% CI 0.05–0.45, p=0.01). Effect stronger in chronic stroke (SMD 0.48).
- Systematic review of reviews (2024): All systematic reviews and 5 meta-analyses reported significant naming improvements following tDCS combined with SLT.
- Subacute aphasia trial (2023): 58 patients randomized to anodal tDCS + naming therapy vs sham. Showed benefit on discourse measures when combined with intensive therapy.
🔹 Clinical Relevance: tDCS for Aphasia
- Target: Left perilesional language areas (anodal) or right Broca's homolog (cathodal)
- Strongest effect: Naming accuracy, particularly in chronic aphasia
- Effect size: Modest (SMD ~0.25–0.48) but consistent across meta-analyses
- Must combine with SLT: tDCS alone is not effective — requires concurrent speech therapy
- Evidence quality: Stronger than motor recovery, but still limited by small studies
Activities of Daily Living
The Cochrane 2020 review found low-to-moderate quality evidence suggesting tDCS might improve ADL capacity. Network meta-analysis suggested cathodal tDCS may be the most promising approach for ADL. However, these results did not persist in sensitivity analyses including only trials with proper allocation concealment, limiting confidence in the findings.
Hemispatial Neglect
Very low quality evidence suggests possible benefit for hemispatial neglect, but data are limited and inconsistent.
Why Have Large Motor Recovery Trials Failed?
🔹 Clinical Relevance: Explaining the Disconnect
Several factors may explain why early promising studies have not translated to positive large RCTs:
- Stimulation intensity: NETS used only 1 mA — potentially subtherapeutic. Current density at the cortex may be insufficient.
- "One-size-fits-all" approach: Standard electrode placements don't account for individual anatomy, lesion location, or skull thickness variability.
- Timing: Optimal timing relative to rehabilitation therapy (before, during, after) is unknown.
- Patient selection: Unlike VNS trials, tDCS trials have not identified responder phenotypes.
- Current diffusion: tDCS current spreads widely — less focal than TMS. May not adequately target M1.
- Lesion heterogeneity: Patients with cortical M1 damage may not benefit from M1 stimulation.
Patient Selection
Unlike VNS (which has defined FMA-UE criteria) or TMS (where MEP status may predict response), no validated selection criteria exist for tDCS. Current considerations are based on limited subgroup analyses:
| Factor | Consideration | Evidence |
|---|---|---|
| Timing post-stroke | Both subacute and chronic studied; unclear which is better | NETS (subacute) and TRANSPORT2 (1–6 mo) both negative |
| Stroke severity | May work better in milder impairment | Limited subgroup data; not established |
| Lesion location | Subcortical may respond better than cortical M1 damage | Theoretical; needs validation |
| For aphasia | Chronic aphasia may show greater benefit than subacute | Meta-analysis: SMD 0.48 in chronic vs 0.25 overall |
Practical Protocol
🔹 Practical Workflow: tDCS Administration
Equipment:
- Battery-powered tDCS stimulator (cost ~$1,000–5,000)
- Saline-soaked sponge electrodes (typically 25–35 cm²)
- Electrode cap or headband for positioning
Standard Parameters:
- Current: 1–2 mA (NETS used 1 mA; some newer studies use 2–4 mA)
- Duration: 20 minutes per session
- Ramp up/down: 8–30 seconds to minimize sensation
- Sessions: 10–20 sessions over 2–4 weeks
Electrode Placement (Motor Recovery):
- Anodal: Anode over C3/C4 (ipsilesional M1 per 10-20 system)
- Reference: Cathode over contralateral supraorbital area
- Dual: Anode ipsilesional M1, cathode contralesional M1
Concurrent Therapy:
- Apply during rehabilitation training for optimal priming
- Can be administered by trained therapists (simpler than TMS)
Safety and Tolerability
tDCS has an excellent safety profile — one of its key advantages over other neuromodulation approaches. No seizures were reported in either the NETS or TRANSPORT2 trials.
| Side Effect | Frequency | Severity |
|---|---|---|
| Tingling/itching under electrodes | Common (30–70%) | Mild, transient |
| Skin redness at electrode site | Common | Mild, resolves quickly |
| Mild headache | Occasional (5–15%) | Mild |
| Fatigue | Occasional | Mild |
| Skin burns (improper use) | Rare | Avoidable with proper technique |
| Seizure | Very rare (<0.01%) | None in major stroke trials |
Contraindications:
- Metallic implants near electrode placement
- Skull defects or craniectomy (alters current flow)
- Skin lesions at electrode sites
- Cardiac pacemakers (relative)
Comparison: tDCS vs TMS vs VNS
| Feature | tDCS | rTMS/TBS | Implanted VNS |
|---|---|---|---|
| Invasiveness | Non-invasive | Non-invasive | Surgical implant |
| Device cost | ~$1,000–5,000 | ~$50,000+ | ~$30,000+ (device + surgery) |
| Portability | Highly portable | Clinic-based | Implanted (always available) |
| Ease of use | Simple (therapist-administered) | Requires trained operator | Patient-controlled after implant |
| Motor evidence | Level B (weak, large RCTs negative) | Level A | Level A (FDA approved) |
| Aphasia evidence | Moderate (naming improvement) | Strong (47 RCTs) | Not studied |
| FDA stroke approval | No | No | Yes (Vivistim 2021) |
| Session duration | 20 min | 3–30 min | Paired with rehab exercises |
🔹 When Might tDCS Still Be Considered?
- Post-stroke aphasia: More consistent evidence for naming improvement as adjunct to SLT
- Resource-limited settings: Low cost and portability make it accessible where TMS unavailable
- Research context: Ongoing trials of higher doses, HD-tDCS, personalized protocols
- Patient preference: Some patients may prefer trying non-invasive approaches before considering VNS surgery
- Not recommended: As first-line neuromodulation for motor recovery given negative large RCT data
Ongoing Research and Future Directions
- Personalized tDCS: MRI-based electrical field modeling to optimize electrode placement and current intensity for individual anatomy
- High-definition tDCS (HD-tDCS): Focal 4×1 ring arrays for more precise targeting — pilot studies ongoing
- Higher doses: Testing whether >2 mA improves efficacy (TRANSPORT2 tested up to 4 mA without benefit)
- Timing optimization: Determining whether tDCS before, during, or after therapy provides greatest benefit
- Biomarker-guided selection: Identifying patients most likely to respond based on connectivity, MEP status, or lesion characteristics
- Combined approaches: tDCS + TMS priming, tDCS + pharmacological enhancement
Limitations and Knowledge Gaps
- Large RCTs consistently negative: NETS and TRANSPORT2 represent high-quality evidence of no benefit for motor recovery
- Optimal parameters unknown: Intensity, duration, electrode placement, timing remain empirical
- Individual variability: High inter-individual differences in response; no predictive biomarkers
- Small effect sizes: Even positive aphasia studies show modest effects (SMD ~0.25)
- No FDA approval: Remains off-label for stroke; cannot bill for treatment
- Limited long-term data: Durability of any benefits is unclear
Key Trials Summary
| Trial/Study | Year | N | Protocol | Population | Key Finding |
|---|---|---|---|---|---|
| NETS | 2024 | 119 | Anodal 1 mA, 10 sessions | Subacute ischemic | Neutral — no difference in FMA-UE |
| TRANSPORT2 | 2025 | 129 | 2 mA or 4 mA + mCIMT | 1–6 months post-stroke | Neutral — no benefit over mCIMT alone |
| Cochrane Review | 2020 | 1,729 | Various | Mixed | Does not support clinical use for ADL/motor |
| Subacute aphasia RCT | 2023 | 58 | Anodal 1 mA + naming therapy | Subacute aphasia | Benefit on discourse measures |
| Aphasia NMA | 2020 | 25 RCTs | Various | Chronic aphasia | Anodal improved functional communication |
| Naming meta-analysis | 2025 | 400 | Various | Post-stroke aphasia | SMD 0.25 for naming (chronic: 0.48) |
| Network meta-analysis (tDCS combinations) | 2025 | 4,335 | 74 RCTs, 11 strategies | Mixed | tDCS + rehab not superior to rehab alone for FMA-UE |
Conclusion
Transcranial direct current stimulation represents one of the most accessible forms of non-invasive brain stimulation — inexpensive, portable, easy to administer, and remarkably safe. However, despite early enthusiasm, large multicenter RCTs have consistently failed to demonstrate benefit for motor recovery after stroke. The NETS and TRANSPORT2 trials, along with Cochrane systematic reviews, do not support routine clinical use of tDCS for motor rehabilitation.
The picture is more encouraging for post-stroke aphasia, where meta-analyses show modest but consistent improvements in naming when tDCS is combined with speech-language therapy. For clinicians seeking evidence-based neuromodulation for motor recovery, TMS (Level A evidence) or implanted VNS (FDA-approved) currently have stronger support than tDCS.
Future research focusing on personalized protocols, higher doses, HD-tDCS, and biomarker-guided patient selection may yet identify subgroups who benefit. For now, tDCS for motor recovery should be considered investigational, while its role in aphasia rehabilitation deserves further clinical development.
References
- NETS Trial Collaboration Group. Efficacy and safety of transcranial direct current stimulation to the ipsilesional motor cortex in subacute stroke (NETS): a multicenter, randomized, double-blind, placebo-controlled trial. Lancet Reg Health Eur. 2024;38:100825.
- TRANSPORT2 Investigators. Safety and efficacy of transcranial direct current stimulation in addition to constraint-induced movement therapy for post-stroke motor recovery: a phase 2, multicentre, randomised, sham-controlled triple-blind trial. Lancet Neurol. 2025.
- Elsner B, Kugler J, Pohl M, Mehrholz J. Transcranial direct current stimulation (tDCS) for improving activities of daily living, and physical and cognitive functioning, in people after stroke. Cochrane Database Syst Rev. 2020;11:CD009645.
- Elsner B, Kugler J, Mehrholz J. Transcranial direct current stimulation (tDCS) for improving aphasia after stroke: a systematic review with network meta-analysis of randomized controlled trials. J Neuroeng Rehabil. 2020;17:88.
- Wang H, et al. Transcranial direct current stimulation for naming disorders in poststroke aphasia: a meta-analysis of randomized controlled trials. Arch Phys Med Rehabil. 2025.
- Stockbridge MD, et al. Transcranial direct-current stimulation in subacute aphasia: a randomized controlled trial. Stroke. 2023;54:912–920.
- Network meta-analysis of tDCS combined with rehabilitation. Front Neurol. 2025;16:1586685.
- Woods AJ, et al. A technical guide to tDCS, and related non-invasive brain stimulation tools. Clin Neurophysiol. 2016;127:1031–1048.